Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Sian E FaustiniAndrew HallSarah R BrownSadie RobertsHarriet HillZania Stamatakinull nullMatthew W JennerRoger G OwenGuy PrattCurly T C M MorrisAlex RichterMark T DraysonMartin F KaiserJennifer L J HeaneyPublished in: British journal of haematology (2023)
Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.
Keyphrases
- sars cov
- coronavirus disease
- respiratory syndrome coronavirus
- multiple myeloma
- newly diagnosed
- end stage renal disease
- immune response
- ejection fraction
- peritoneal dialysis
- prognostic factors
- study protocol
- stem cells
- cross sectional
- gene expression
- copy number
- intellectual disability
- dna methylation
- bone marrow
- phase ii
- autism spectrum disorder
- single molecule
- mass spectrometry
- replacement therapy